Novo launched oral Wegovy in January and surpassed three million US prescriptions in just over five months, after reaching one million prescriptions in 12 weeks, but Lillys orforglipron, sold as Foundayo, beat oral semaglutide on A1C and weight in the ACHIEVE-3 type 2 diabetes head-to-head trial
& Buckley, C
However, they will not address any underlying causes of the headache, like dehydration
Who should absolutely not take tirzepatide
however, the incidence of other side effects was generally similar between groups and there were no concerning changes in neurocognitive function ( Conclusions We conclude that, among youth with obesity prescribed topiramate plus lifestyle modification in a pediatric weight management clinical setting, mean percent change in %BMIp95 and BMI were both significantly reduced at 1.5, 3, 6, and 12 months after initiation, with %BMIp95 reductions from baseline of 2.2, 3.9, 6.6, and 9.3 percentage points at these time points